Agenda
Radiation Countermeasures Symposium, June 15, 2011

NOTE:  If using Internet Explorer browser version 9 (IE9), Compatibility View recommended (details via Microsoft website).

Symposium sponsored by

The Armed Forces Radiobiology Research Institute at the Uniformed Services University in Bethesda, Maryland

Venue

Sanford Auditorium
4301 Jones Bridge Road, Bethesda, MD


June 15, 2011

TIME

EVENT

7:30 a.m. 

Registration

8:00 a.m. 

Opening Remarks
Christopher R. Lissner, PhD, Scientific Director
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

8:10 a.m.

Administrative Remarks
Matthew W. DeShazo, LT, MSC, USN, Department Head, Administrative Services
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

8:15 a.m.

Introduction
Mark H. Whitnall, PhD, Program Advisor, Radiation Countermeasures
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

8:30 a.m.

Modeling the Effects of Nuclear Weapons in an Urban Setting
Kyle Millage, CHP, PE, Group Leader of Nuclear and Radiation Effects
Applied Research Associates, Inc. in Arlington, Virginia

8:55 a.m.

FDA Perspective on Radiation Countermeasure Development
Alla Shapiro, MD, PhD, Medical Officer in the Office of Counter-Terrorism and Emergency Coordination, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Department of Health and Human Services in Silver Spring, Maryland

9:20 a.m.

Bacteria and Antibiotics in the Context of the Acute Radiation Syndrome
Thomas B. Elliott, PhD, Research Microbiologist
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

9:45 a.m.

Mixed Neutron/Gamma Fields: Acute Radiation Syndrome and Countermeasure Efficacy
G. David Ledney, PhD, Principal Investigator
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

10:10 a.m.

Break

10:30 a.m.

Cytokines in the Treatment of Radiation Injury
Thomas J. MacVittie, PhD, Professor, and Ann Farese, MS, Research Associate, Departments of Radiation Oncology and Pathology, University of Maryland School of Medicine, Baltimore, Maryland

10:55 a.m.

NIAID/NIH Radiation/Nuclear Medical Countermeasures Development Program
Bert W. Maidment, PhD, Associate Director of Product Development, Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, Maryland

11:20 a.m.

Discovery and Development of Genistein as a Radioprotective Agent
Michael R. Landauer, PhD, Principal Investigator
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

11:45 a.m.

Administration of Myeloid Progenitor Cells to Treat the Acute Radiation Syndrome
Vijay K. Singh, PhD, Principal Investigator
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

12:10 p.m.

Lunch

1:30 p.m.

Development of Ex-RAD® as a Radiation Countermeasure
Sanchita P. Ghosh, PhD, Principal Investigator
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

1:55 p.m.

Targeting HMG-CoA Reductase for Radioprotection—Past, Present, and Future
Martin Hauer-Jensen, MD, PhD, FACS, Director of the Division of Radiation Health and K. Sree Kumar, PhD, Research Chemist University of Arkansas for Medical Sciences in Little Rock, Arkansas and Armed Forces Radiobiology Research Institute in Bethesda, Maryland (respectively)

2:20 p.m.

Development of Novel Acute and Delayed Radiation Effects Countermeasures
Alexandra C. Miller, PhD, Senior Scientist, Program Advisor, Delayed Radiation Effects
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

2:45 p.m.

Delta-Tocotrienol: Radiation Protection and Effects on Signal Transduction Pathways
Venkataraman Srinivasan, PhD, and Mang Xiao, MD, Principal Investigators
Armed Forces Radiobiology Research Institute in Bethesda, Maryland

3:10 p.m.

Break

3:30 p.m.

Protectan CBLB502 on the "Animal Rule" Path: Efficacy, Mechanism of Action and Human Dose Finding
Andrei V. Gudkov, PhD, DSci, Senior Vice President for Basic Science and Chair of the Department of Cell Stress Biology at the Roswell Park Cancer Institute and Chief Scientific Officer at Cleveland BioLabs, Inc., in Buffalo, New York

3:55 p.m.

Biomedical Advanced Research and Development Authority, Radiation Countermeasures Program
Ronald Manning, PhD, Chief of the Chemical, Radiological and Nuclear Medical Countermeasures Division Biomedical Advanced Research and Development Authority in Washington, D.C. (presented by Brian Moyer, PhD)

4:20 p.m.

DoD Acquisition Guidelines and Practices for Advanced Development of Radiation Countermeasures
Alan H. Epstein, MD, Senior Medical Radiation Advisor, Chemical Biological Medical Systems—Medical Identification and Treatment Systems, Joint Program, Executive Office for Chemical and Biological Defense in Falls Church, Virginia

4:45 p.m.

Adjourn

Contact symposium chairman, Dr. Mark Whitnall (whitnall@afrri.usuhs.mil or 301-295-9262), or symposium officer-in-charge, CPT Anthony Kang (kang@afrri.usuhs.mil or 301-295-0507), to RSVP or learn more about the events.

TOP OF PAGE